Medicus Pharma Posts $15.2 Million Q3 Loss

The biopharmaceutical company shifted spending toward its CD228V antibody-drug conjugate as it reported third-quarter 2026 results.

Updated on Nov. 9, 2026 in Corporate Finance

Photograph of a clean stainless-steel laboratory bench with an amber glass vial and pipette rack in soft window light.
Medicus Pharma reported a $15.2 million third-quarter net loss as it redirected spending toward its CD228V antibody-drug conjugate program. AI Illustration. Upload story photo >

Medicus Pharma reported a net loss of $15.2 million, or $11.64 per share, for the three months ended September 30, 2026, compared with $16 million a year earlier. The company completed a 50-for-1 share consolidation effective October 12.

Why it matters

Medicus is directing its development resources toward CD228V, which it treats as its principal development priority under an exclusive license from Pfizer. The company's cash position and planned business combination with SkinJect will shape its financial trajectory in the coming quarters.

Operating expenses fell to $14.5 million from $15.4 million a year earlier, while research and development rose to $2 million from $1.7 million. Medicus ended the quarter with $13.1 million in cash, and whether CD228V's projected response rate holds in trials remains unproven.

The players

Medicus Pharma

A clinical-stage biopharmaceutical company developing CD228V and other therapies under an exclusive license from Pfizer.

Pfizer

A major global pharmaceutical company that licensed CD228V to Medicus and provided $2 million in development funding.

The details

Medicus raised approximately $42.6 million through equity and secured debt financings during the first nine months of 2026 and repaid $6.4 million in debt. Pfizer has provided $2 million in development funding for CD228V, and a non-binding letter of intent values SkinJect at approximately $135 million in pre-money enterprise value.

Timeline

  1. September 30, 2026: End of the third-quarter reporting period.

  2. October 12, 2026: The 50-for-1 share consolidation took effect.

  3. First half of 2027: Medicus expects to complete the SkinJect business combination.

Market Dynamics

Medicus's focus on CD228V, an antibody-drug conjugate licensed from Pfizer, places it within the broader wave of ADC development that has attracted large pharmaceutical licensing deals. The company's reliance on partner funding and equity raises reflects how smaller biotechs often depend on such arrangements to advance late-stage candidates.

Shareholders face a 50-for-1 share consolidation that changes the per-share figures they hold. Investors tracking the company should watch the pending SkinJect combination, which is expected in the first half of 2027.

The takeaway

Biotech investors should weigh reported losses alongside cash runway and partner-funded programs. Medicus's trajectory will depend on whether early CD228V data supports its projections.

Further reading

Explore more Corporate Finance coverage to see how biotech companies manage cash and partnerships.